COVID 19 Spike RBD Brazil Variant Coronavirus (COVID-19) Recombinant Protein

Description: Recombinant spike RBD (K417T, E484K, N501Y) protein of SARS-CoV-2 Brazil variant (B.1.1.248) expressed and purified from HEK293 cells. The binding activity has been tested using human ACE2 protein in a functional ELISA assay.

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2) is the virus that causes COVID-19 (coronavirus disease 2019), the respiratory illness responsible for the COVID-19 pandemic. Many SARS-CoV-2 variants have been identified throughout the world since it’s outbreak in late 2019; some are believed or have been believed to be of particular importance due to their potential for increased transmissibility, increased virulence, and reduced effectiveness of vaccines against them.

The genome of SARS-CoV-2 has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses. However, the external subdomain of Spike's receptor binding domain (RBD) of SARS-CoV-2 shares only 40% amino acid identity with other SARS-related coronaviruses.

Small volumes of COVID-19 recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS434292 is a recombinant protein targeting COVID-19. Also known as Recombinant Spike RBD Protein of SARS-CoV-2 Brazil Variant. Host: HEK293 Cells.